Compare Enveric Biosciences Inc (ENVB) vs Equinix Inc (EQIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Equinix Inc — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while Equinix Inc trades at $1,008.4 (market cap $100.85B). The key difference: Equinix Inc is far larger — about 18956.8× Enveric Biosciences Inc's market cap, and Equinix Inc pays a 1.93% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | EQIX | |
|---|---|---|
Market Cap | $5.32M | $100.85B |
Sector | Health | Real Estate |
52-Week High | $17.40 | $1.12K |
52-Week Low | $1.28 | $726.09 |
Enterprise Value | $408.82K | $121.14B |
Dividend Yield | — | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Equinix (EQIX) trades at $1,005.31, down 1.78% today, with a bearish technical signal despite strong analyst support. The company reported mixed Q1 2026 earnings with a slight miss on EPS expectations but maintains robust revenue growth and profitability. Recent partnerships with Cisco and NVIDIA position EQIX well for AI infrastructure demand, though high valuation ratios and negative cash flow trends present challenges.
The outlook remains cautiously optimistic with 74.5% analyst buy ratings and a $1,110 consensus price target suggesting 10% upside. Key risks include elevated debt levels, aggressive capital expenditure, and competitive pressures in the data center REIT sector. The stock offers exposure to digital infrastructure growth but requires monitoring of cash flow sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →
